Journal of Pharmaceutical Research

References

1. Kumar PJ, Clark M. Textbook of Clinical Medicine. 2002. Pub: Saunders (London).:1099-121.

2. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO Consultation criteria, and 1985 WHO criteria. Diabetes Research and Clinical Practice. 1999; 44 (1). Available from: https://doi.org/10.1016/s0168-8227(99)00008-x

3. Beverley B, Eschwège E. The diagnosis and classification of diabetes and impaired glucose tolerance. Textbook of Diabetes. 2003;1:2-1.

4. Lindberg G, Lindblad U, Melander A. Sulfonylureas for treating type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2008; Available from: https://doi.org/10.1002/14651858.cd003888.pub2

5. Bearse MA, Han Y, Schneck ME, Barez S, Jacobsen C, Adams AJ. Local Multifocal Oscillatory Potential Abnormalities in Diabetes and Early Diabetic Retinopathy. Investigative Opthalmology & Visual Science. 2004; 45 (9). Available from: https://doi.org/10.1167/iovs.04-0308

6. Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Århus County, Denmark. Acta Ophthalmologica Scandinavica. 2004; 82 (4). Available from: https://doi.org/10.1111/j.1600-0420.2004.00270.x

7. Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, et al. Involvement of Brain-Derived Neurotrophic Factor in Early Retinal Neuropathy of Streptozotocin-Induced Diabetes in Rats. Diabetes. 2004; 53 (9). Available from: https://doi.org/10.2337/diabetes.53.9.2412

8. Moran A, Palmas W, Field L, Bhattarai J, Schwartz JE, Weinstock RS, et al. Cardiovascular Autonomic Neuropathy Is Associated With Microalbuminuria in Older Patients With Type 2 Diabetes. Diabetes Care. 2004; 27 (4). Available from: https://doi.org/10.2337/diacare.27.4.972

9. Huang C, Kim Y, Caramori ML, Fish AJ, Rich SS, Miller ME, et al. Cellular Basis of Diabetic Nephropathy. Diabetes. 2002; 51 (12). Available from: https://doi.org/10.2337/diabetes.51.12.3577

10. Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Venkat Narayan KM, Knowler WC, et al. Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. Diabetologia. 2003; 46 (6). Available from: https://doi.org/10.1007/s00125-003-1104-x

11. Svensson M, Eriksson JW, Dahlquist G. Early Glycemic Control, Age at Onset, and Development of Microvascular Complications in Childhood-Onset Type 1 Diabetes. Diabetes Care. 2004; 27 (4). Available from: https://doi.org/10.2337/diacare.27.4.955

12. Saely CH, Aczel S, Marte T, Langer P, Drexel H. Cardiovascular complications in Type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetic state. Diabetologia. 2004; 47 (1). Available from: https://doi.org/10.1007/s00125-003-1274-6

13. Wallace C, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S, et al. Incidence of Falls, Risk Factors for Falls, and Fall-Related Fractures in Individuals With Diabetes and a Prior Foot Ulcer. Diabetes Care. 2002; 25 (11). Available from: https://doi.org/10.2337/diacare.25.11.1983

14. Centers for Disease Control and Prevention (CDC). Prevalence of diabetes among Native Americans and Alaska Natives, 1990-1997: an increasing burden.. Morbidity and Mortality Weekly Report. 2003; 52 (45). Available from: https://pubmed.ncbi.nlm.nih.gov/14614407/

15. Amos AF, McCarty DJ, Zimmet P. The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010. Diabetic Medicine. 1997; 14 (S5). Available from: https://doi.org/10.1002/(sici)1096-9136(199712)14:5+3.0.co;2-r

16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabetic Medicine. 1998; 15 (7). Available from: https://doi.org/10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s

17. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical Practice. 2011; 94 (3). Available from: https://doi.org/10.1016/j.diabres.2011.10.029

18. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services. Atlanta (GA): Centers for Disease Control and Prevention; 2011.

19. King H, Aubert RE, Herman WH. Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21 (9). Available from: https://doi.org/10.2337/diacare.21.9.1414

20. Chowdhury TA, Lasker SS. Complications and cardiovascular risk factors in South Asians and Europeans with early-onset type 2 diabetes. QJM. 2002; 95 (4). Available from: https://doi.org/10.1093/qjmed/95.4.241

21. Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney International Supplements. 2015; 5 (1). Available from: https://doi.org/10.1038/kisup.2015.2

22. Young-Hyman DL. National Institute of Diabetes and Digestive and Kidney Diseases. Encyclopedia of Behavioral Medicine. 2020; Available from: https://doi.org/10.1007/978-3-030-39903-0_764

23. Ramachandran A. Epidemiology of diabetes in India—three decades of research. Journal of the Association of Physicians of India. 2005; 53 Available from: https://pubmed.ncbi.nlm.nih.gov/15857011/

24. Ramachandran A. Socio-economic burden of diabetes in India. Journal of the Association of Physicians of India. 2007; 55 (Suppl). Available from: https://pubmed.ncbi.nlm.nih.gov/17927005/

25. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care. 2005; 28 (1). Available from: https://doi.org/10.2337/diacare.28.1.164

26. US Renal Data System. USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Digestive and Kidney Diseases, Vol. 2014. 2013.

27. Shlipak M. Diabetic nephropathy: preventing progression. BMJ clinical evidence. 2010; 2010 Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3217768/

28. Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L, et al. Trends in the Prevalence and Ratio of Diagnosed to Undiagnosed Diabetes According to Obesity Levels in the U.S.. Diabetes Care. 2004; 27 (12). Available from: https://doi.org/10.2337/diacare.27.12.2806

29. Mogensen CE, Christensen CK. Predicting Diabetic Nephropathy in Insulin-Dependent Patients. New England Journal of Medicine. 1984; 311 (2). Available from: https://doi.org/10.1056/nejm198407123110204

30. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population. Circulation. 2002; 106 (14). Available from: https://doi.org/10.1161/01.cir.0000031732.78052.81

31. Atkins RC, Polkinghorne KR, Briganti EM, Shaw JE, Zimmet PZ, Chadban SJ. Prevalence of albuminuria in Australia: The AusDiab Kidney Study. Kidney International. 2004; 66 Available from: https://doi.org/10.1111/j.1523-1755.2004.09206.x

32. Sviridov D, Meilinger B, Drake SK, Hoehn GT, Hortin GL. Coelution of Other Proteins with Albumin during Size-Exclusion HPLC: Implications for Analysis of Urinary Albumin. Clinical Chemistry. 2006; 52 (3). Available from: https://doi.org/10.1373/clinchem.2005.057323

33. Brosius III FC, Heilig CW. Glucose transporters in diabetic nephropathy. Pediatric Nephrology. 2005; 20 (4). Available from: https://doi.org/10.1007/s00467-004-1748-x

34. Chung SS, Ho EC, Lam KS, Chung SK. Contribution of Polyol Pathway to Diabetes-Induced Oxidative Stress. Journal of the American Society of Nephrology. 2003; 14 (suppl_3). Available from: https://doi.org/10.1097/01.asn.0000077408.15865.06

35. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in Diabetic Nephropathy. Seminars in Nephrology. 2007; 27 (2). Available from: https://doi.org/10.1016/j.semnephrol.2007.01.006

36. Jakuš V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications.. Physiological Research. 2004; 53 (2). Available from: https://doi.org/10.33549/physiolres.930430

37. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, et al. Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C-α−Dependent Pathway. Diabetes. 2004; 53 (11). Available from: https://doi.org/10.2337/diabetes.53.11.2921

38. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, et al. Protein Kinase C–Dependent Increase in Reactive Oxygen Species (ROS) Production in Vascular Tissues of Diabetes. Journal of the American Society of Nephrology. 2003; 14 (suppl_3). Available from: https://doi.org/10.1097/01.asn.0000077407.90309.65

39. Leask A, Abraham DJ. TGF‐β signaling and the fibrotic response. The FASEB Journal. 2004; 18 (7). Available from: https://doi.org/10.1096/fj.03-1273rev

40. Wolf G. Renal injury due to renin–angiotensin–aldosterone system activation of the transforming growth factor-β pathway. Kidney International. 2006; 70 (11). Available from: https://doi.org/10.1038/sj.ki.5001846

41. Schiffer M, Von Gersdorff G, Bitzer M, Susztak K, Böttinger EP. Smad proteins and transforming growth factor-β signaling. Kidney International. 2000; 58 Available from: https://doi.org/10.1046/j.1523-1755.2000.07708.x

42. Ha H, Lee HB. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology. 2005; 10 (s2). Available from: https://doi.org/10.1111/j.1440-1797.2005.00448.x

43. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive Oxygen Species-Regulated Signaling Pathways in Diabetic Nephropathy. Journal of the American Society of Nephrology. 2003; 14 (suppl_3). Available from: https://doi.org/10.1097/01.asn.0000077410.66390.0f

44. Djordjević VB. Free Radicals in Cell Biology. International Review of Cytology. 2004; Available from: https://doi.org/10.1016/s0074-7696(04)37002-6

45. Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, Matsuo T, et al. Reactive Oxygen Species from Mitochondria Induce Cyclooxygenase-2 Gene Expression in Human Mesangial Cells. Diabetes. 2003; 52 (10). Available from: https://doi.org/10.2337/diabetes.52.10.2570

46. Craven PA, Melhem MF, Phillips SL, DeRubertis FR. Overexpression of Cu2+/Zn2+ Superoxide Dismutase Protects Against Early Diabetic Glomerular Injury in Transgenic Mice. Diabetes. 2001; 50 (9). Available from: https://doi.org/10.2337/diabetes.50.9.2114

47. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. European Journal of Clinical Investigation. 2004; 34 (12). Available from: https://doi.org/10.1111/j.1365-2362.2004.01429.x

48. Jandeleit-Dahm K, Cooper ME. Hypertension and Diabetes: Role of the Renin-Angiotensin System. Endocrinology and Metabolism Clinics of North America. 2006; 35 (3). Available from: https://doi.org/10.1016/j.ecl.2006.06.007

49. Giunti S, Barit D, Cooper ME. Mechanisms of Diabetic Nephropathy. Hypertension. 2006; 48 (4). Available from: https://doi.org/10.1161/01.hyp.0000240331.32352.0c

50. Danilczyk U, Penninger JM. Angiotensin-Converting Enzyme II in the Heart and the Kidney. Circulation Research. 2006; 98 (4). Available from: https://doi.org/10.1161/01.res.0000205761.22353.5f

51. Werner E. GTPases and reactive oxygen species: switches for killing and signaling. Journal of Cell Science. 2004; 117 (2). Available from: https://doi.org/10.1242/jcs.00937

52. Lin S, Chugh S, Pan X, Wallner EI, Wada J, Kanwar YS. Identification of up-regulated Ras-like GTPase, Rap1b, by suppression subtractive hybridization. Kidney International. 2001; 60 (6). Available from: https://doi.org/10.1046/j.1523-1755.2001.00061.x

53. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proceedings of the National Academy of Sciences. 2002; 99 (12). Available from: https://doi.org/10.1073/pnas.122228799

54. Zeng L, Xu H, Chew TL, Chisholm R, Sadeghi MM, Kanwar YS, et al. Simvastatin Modulates Angiotensin II Signaling Pathway by Preventing Rac1-Mediated Upregulation of p27. Journal of the American Society of Nephrology. 2004; 15 (7). Available from: https://doi.org/10.1097/01.asn.0000129839.91567.68

55. Wolf G. Molecular Mechanisms of Diabetic Mesangial Cell Hypertrophy. Journal of the American Society of Nephrology. 2002; 13 (10). Available from: https://doi.org/10.1681/asn.v13102611

56. Santerre R. Impact of GPS satellite sky distribution. manuscripta geodaetica. 1991; 16 (1). Available from: https://doi.org/10.1007/bf03655285

57. Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, Anai M, et al. Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia. 1993; 36 (11). Available from: https://doi.org/10.1007/bf00401058

58. Efrat S, Surana M, Fleischer N. Glucose induces insulin gene transcription in a murine pancreatic beta-cell line. Journal of Biological Chemistry. 1991; 266 (17). Available from: https://doi.org/10.1016/s0021-9258(18)99139-8

59. Carrington ME. Effective potential at finite temperature in the standard model. Physical Review D. 1992; 45 (8). Available from: https://doi.org/10.1103/physrevd.45.2933

60. Afari EA, Akanmori BD, Nakano T, Ofori-Adjei D. Plasmodium falciparum: sensitivity to chloroquine in vivo in three ecological zones in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1992; 86 (3). Available from: https://doi.org/10.1016/0035-9203(92)90285-k

61. Gazdar AF, Chick WL, Oie HK, Sims HL, King DL, Weir GC, et al. Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor.. Proceedings of the National Academy of Sciences. 1980; 77 (6). Available from: https://doi.org/10.1073/pnas.77.6.3519

62. Radvanyi F, Christgau S, Baekkeskov S, Jolicoeur C, Hanahan D. Pancreatic β Cells Cultured from Individual Preneoplastic Foci in a Multistage Tumorigenesis Pathway: a Potentially General Technique for Isolating Physiologically Representative Cell Lines. Molecular and Cellular Biology. 1993; 13 (7). Available from: https://doi.org/10.1128/mcb.13.7.4223-4232.1993

63. Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, Nagai Y. p60v‐src causes tyrosine phosphorylation and inactivation of the N‐cadherin‐catenin cell adhesion system.. The EMBO Journal. 1993; 12 (1). Available from: https://doi.org/10.1002/j.1460-2075.1993.tb05658.x

64. McClenaghan NH, Flatt PR. Engineering cultured insulin-secreting pancreatic B-cell lines. Journal of Molecular Medicine. 1999; 77 (1). Available from: https://doi.org/10.1007/s001090050344

65. Dufayet de la Tour D, Halvorsen T, Demeterco C, Tyrberg B, Itkin-Ansari P, Loy M, et al. β-Cell Differentiation from a Human Pancreatic Cell Line in Vitro and in Vivo. Molecular Endocrinology. 2001; 15 (3). Available from: https://doi.org/10.1210/mend.15.3.0604

66. Tan H, Chen J, Li Y, Li Y, Zhong Y, Li G, et al. Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF/Akt/ERK pathways. Molecular Medicine. 2022; 28 (1). Available from: https://doi.org/10.1186/s10020-022-00481-w

67. Giralt-López A, Molina-Van den Bosch M, Vergara A, García-Carro C, Seron D, Jacobs-Cachá C, et al. Revisiting Experimental Models of Diabetic Nephropathy. International Journal of Molecular Sciences. 2020; 21 (10). Available from: https://doi.org/10.3390/ijms21103587

68. Gondaliya P, Dasare A, Srivastava A, Kalia K. miR29b regulates aberrant methylation in In-Vitro diabetic nephropathy model of renal proximal tubular cells. PLOS ONE. 2018; 13 (11). Available from: https://doi.org/10.1371/journal.pone.0208044

69. Tanaka M, Giménez-Llort L. Emerging Translational Research in Neurological and Psychiatric Diseases: From In Vitro to In Vivo Models. 2023; Available from: https://doi.org/10.3390/books978-3-0365-9657-0

70. Xie K, Ma Y, Din J, Jin Y, Zhang S, Liu S, et al. Research and advances in mouse models of diabetic nephropathy: a narrative review. BMC Nephrology. 2025; 26 (1). Available from: https://doi.org/10.1186/s12882-025-04432-5

71. Zou H, Zhou B, Xu G. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovascular Diabetology. 2017; 16 (1). Available from: https://doi.org/10.1186/s12933-017-0547-1

72. Yan LJ. The Nicotinamide/Streptozotocin Rodent Model of Type 2 Diabetes: Renal Pathophysiology and Redox Imbalance Features. Biomolecules. 2022; 12 (9). Available from: https://doi.org/10.3390/biom12091225

73. Kitada M, Ogura Y, Koya D. Rodent models of diabetic nephropathy: their utility and limitations. International Journal of Nephrology and Renovascular Disease. 2016; Volume 9 Available from: https://doi.org/10.2147/ijnrd.s103784

74. Yang Y, He X, Liu W, Mu L, Wang S. Comprehensive bioinformatics and in vivo validation reveal key molecular drivers of diabetic nephropathy progression. Frontiers in Endocrinology. 2025; 16 Available from: https://doi.org/10.3389/fendo.2025.1654401

75. Betz B, Conway BR. An Update on the Use of Animal Models in Diabetic Nephropathy Research. Current Diabetes Reports. 2016; 16 (2). Available from: https://doi.org/10.1007/s11892-015-0706-2

76. Betz B, Conway BR. An Update on the Use of Animal Models in Diabetic Nephropathy Research. Current Diabetes Reports. 2016; 16 (2). Available from: https://doi.org/10.1007/s11892-015-0706-2

77. Giralt-López A, Molina-Van den Bosch M, Vergara A, García-Carro C, Seron D, Jacobs-Cachá C, et al. Revisiting Experimental Models of Diabetic Nephropathy. International Journal of Molecular Sciences. 2020; 21 (10). Available from: https://doi.org/10.3390/ijms21103587

78. Liu M, Cardilla A, Ngeow J, Gong X, Xia Y. Studying Kidney Diseases Using Organoid Models. Frontiers in Cell and Developmental Biology. 2022; 10 Available from: https://doi.org/10.3389/fcell.2022.845401

79. BenchChem Technical Support Team. A Comparative Guide to Long-Term Diabetic Complications in Alloxan and Streptozotocin (STZ) Rat Models. May 2026.

80. Li H, Qin F, Zheng S, Wu J, Lin S, Gao X, et al. Construction and evaluation of STZ-induced diabetes and diabetic kidney disease models in C57BL/6J mice. Frontiers in Endocrinology. 2025; 16 Available from: https://doi.org/10.3389/fendo.2025.1711035

81. Liu M, Cardilla A, Ngeow J, Gong X, Xia Y. Studying Kidney Diseases Using Organoid Models. Frontiers in Cell and Developmental Biology. 2022; 10 Available from: https://doi.org/10.3389/fcell.2022.845401

82. Nakanoh H, Tsuji K, Fukushima K, Uchida N, Haraguchi S, Kitamura S, et al. Kidney Organoids: Current Advances and Applications. Life. 2025; 15 (11). Available from: https://doi.org/10.3390/life15111680

83. Tabibzadeh N, Morizane R. Advancements in therapeutic development: kidney organoids and organs on a chip. Kidney International. 2024; 105 (4). Available from: https://doi.org/10.1016/j.kint.2023.11.035

84. Li F, Ma Z, Cai Y, Zhou J, Liu R. Optimizing diabetic kidney disease animal models: Insights from a meta‐analytic approach. Animal Models and Experimental Medicine. 2023; 6 (5). Available from: https://doi.org/10.1002/ame2.12350

85. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological Research. 2001; Available from: https://doi.org/10.33549/physiolres.930111

86. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian Journal of Medical Research. 2007; 125 (3). Available from: https://pubmed.ncbi.nlm.nih.gov/17496368/

87. Mark A. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clinical Journal of the American Society of Nephrology. 2012; 7 (10). Available from: https://doi.org/10.2215/cjn.02780312

88. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacological Research. 2005; 52 (4). Available from: https://doi.org/10.1016/j.phrs.2005.05.004

89. Forbes JM, Cooper ME. Mechanisms of Diabetic Complications. Physiological Reviews. 2013; 93 (1). Available from: https://doi.org/10.1152/physrev.00045.2011

90. Barrière DA, Noll C, Roussy G, Lizotte F, Kessai A, Kirby K, et al. Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications. Scientific Reports. 2018; 8 (1). Available from: https://doi.org/10.1038/s41598-017-18896-5

91. Marie Skłodowska-Curie Diabetic nephropathy modelling in hESC-derived 3D kidney organoids. European Commission, 2021.

92. Qian Z, Chen Y, Ran Y, Da Jingjing ZY. Diabetic nephropathy model: animal model, two-dimensional cell simulation and three-dimensional organoid model. Chinese Journal of Tissue Engineering Research. 2025 Jun 18;29(17):3632.

93. Li T, Chen K, Sun Y, Zhang L. Diabetic kidney disease: integrating multi-omics insights, artificial intelligence, and novel therapeutics for precision medicine. Frontiers in Genetics. 2026; 17 Available from: https://doi.org/10.3389/fgene.2026.1760654

94. Wani ZA, Ahmed S, Saleh A, Anna VR, Fahelelbom KM, Raju SK, et al. Biomarkers in diabetic nephropathy: A comprehensive review of their role in early detection and disease progression monitoring. Diabetes Research and Clinical Practice. 2025; 226 Available from: https://doi.org/10.1016/j.diabres.2025.112292

95. Ahire YS, Bairagi VA, Dongre RS, Patil JH, Jadhav SB. Cinnamon-derived cinnamaldehyde and empagliflozin combination for HFD and STZ-induced diabetic nephropathy: An experimental study. Degrés Journal. 2026;11(4):1-20.